398 related articles for article (PubMed ID: 28577078)
21. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer.
Takahashi Y; Iwamoto T; Suzuki Y; Kajiwara Y; Hatono M; Tsukioki T; Kawada K; Kochi M; Ikeda H; Shien T; Taira N; Matsuoka J; Doihara H; Toyooka S
Clin Breast Cancer; 2020 Apr; 20(2):117-124.e4. PubMed ID: 31570267
[TBL] [Abstract][Full Text] [Related]
23. Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel.
Sharma P; López-Tarruella S; García-Saenz JA; Khan QJ; Gómez HL; Prat A; Moreno F; Jerez-Gilarranz Y; Barnadas A; Picornell AC; Monte-Millán MD; González-Rivera M; Massarrah T; Pelaez-Lorenzo B; Palomero MI; González Del Val R; Cortés J; Fuentes-Rivera H; Morales DB; Márquez-Rodas I; Perou CM; Lehn C; Wang YY; Klemp JR; Mammen JV; Wagner JL; Amin AL; O'Dea AP; Heldstab J; Jensen RA; Kimler BF; Godwin AK; Martín M
Clin Cancer Res; 2018 Dec; 24(23):5820-5829. PubMed ID: 30061361
[TBL] [Abstract][Full Text] [Related]
24. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
[TBL] [Abstract][Full Text] [Related]
25. Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients.
Romero A; García-Sáenz JA; Fuentes-Ferrer M; López Garcia-Asenjo JA; Furió V; Román JM; Moreno A; de la Hoya M; Díaz-Rubio E; Martín M; Caldés T
Ann Oncol; 2013 Mar; 24(3):655-61. PubMed ID: 23104719
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Breast Cancer Staging Systems After Neoadjuvant Chemotherapy.
Kantor O; Laws A; Pastorello RG; King C; Wong S; Dey T; Schnitt S; King TA; Mittendorf EA
Ann Surg Oncol; 2021 Nov; 28(12):7347-7355. PubMed ID: 33956276
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
Esserman LJ; Berry DA; Cheang MC; Yau C; Perou CM; Carey L; DeMichele A; Gray JW; Conway-Dorsey K; Lenburg ME; Buxton MB; Davis SE; van't Veer LJ; Hudis C; Chin K; Wolf D; Krontiras H; Montgomery L; Tripathy D; Lehman C; Liu MC; Olopade OI; Rugo HS; Carpenter JT; Livasy C; Dressler L; Chhieng D; Singh B; Mies C; Rabban J; Chen YY; Giri D; Au A; Hylton N;
Breast Cancer Res Treat; 2012 Apr; 132(3):1049-62. PubMed ID: 22198468
[TBL] [Abstract][Full Text] [Related]
28. Time to surgery following neoadjuvant chemotherapy for breast cancer impacts residual cancer burden, recurrence, and survival.
Sutton TL; Schlitt A; Gardiner SK; Johnson N; Garreau JR
J Surg Oncol; 2020 Dec; 122(8):1761-1769. PubMed ID: 33125715
[TBL] [Abstract][Full Text] [Related]
29. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
[TBL] [Abstract][Full Text] [Related]
30. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.
Hylton NM; Blume JD; Bernreuter WK; Pisano ED; Rosen MA; Morris EA; Weatherall PT; Lehman CD; Newstead GM; Polin S; Marques HS; Esserman LJ; Schnall MD;
Radiology; 2012 Jun; 263(3):663-72. PubMed ID: 22623692
[TBL] [Abstract][Full Text] [Related]
31. Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy.
Promberger R; Dubsky P; Mittlböck M; Ott J; Singer C; Seemann R; Exner R; Panhofer P; Steger G; Bergen E; Gnant M; Jakesz R; Bago-Horvath Z; Rudas M; Bartsch R
Clin Breast Cancer; 2015 Dec; 15(6):505-11. PubMed ID: 26195436
[TBL] [Abstract][Full Text] [Related]
32. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.
Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA
Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy.
Hamy AS; Darrigues L; Laas E; De Croze D; Topciu L; Lam GT; Evrevin C; Rozette S; Laot L; Lerebours F; Pierga JY; Osdoit M; Faron M; Feron JG; Laé M; Reyal F
PLoS One; 2020; 15(6):e0234191. PubMed ID: 32579551
[TBL] [Abstract][Full Text] [Related]
34. Significance of acellular mucin pools in rectal carcinoma after neoadjuvant chemoradiotherapy.
Shia J; McManus M; Guillem JG; Leibold T; Zhou Q; Tang LH; Riedel ER; Weiser MR; Paty PB; Temple LK; Nash G; Kolosov K; Minsky BD; Wong WD; Klimstra DS
Am J Surg Pathol; 2011 Jan; 35(1):127-34. PubMed ID: 21164296
[TBL] [Abstract][Full Text] [Related]
35. Residual Cancer Burden Class Associated with Survival Outcomes in Women with Different Phenotypic Subtypes of Breast Cancer After Neoadjuvant Chemotherapy.
Elder EA; Livasy CA; Donahue EE; Neelands B; Patrick A; Needham M; Sarantou T; Hadzikadic-Gusic L; Heeke AL; White RL
Ann Surg Oncol; 2022 Dec; 29(13):8060-8069. PubMed ID: 35980548
[TBL] [Abstract][Full Text] [Related]
36. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
[TBL] [Abstract][Full Text] [Related]
37. Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer.
Vila J; Teshome M; Tucker SL; Woodward WA; Chavez-MacGregor M; Hunt KK; Mittendorf EA
Ann Surg; 2017 Mar; 265(3):574-580. PubMed ID: 27735826
[TBL] [Abstract][Full Text] [Related]
38. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
Symmans WF; Yau C; Chen YY; Balassanian R; Klein ME; Pusztai L; Nanda R; Parker BA; Datnow B; Krings G; Wei S; Feldman MD; Duan X; Chen B; Sattar H; Khazai L; Zeck JC; Sams S; Mhawech-Fauceglia P; Rendi M; Sahoo S; Ocal IT; Fan F; LeBeau LG; Vinh T; Troxell ML; Chien AJ; Wallace AM; Forero-Torres A; Ellis E; Albain KS; Murthy RK; Boughey JC; Liu MC; Haley BB; Elias AD; Clark AS; Kemmer K; Isaacs C; Lang JE; Han HS; Edmiston K; Viscusi RK; Northfelt DW; Khan QJ; Leyland-Jones B; Venters SJ; Shad S; Matthews JB; Asare SM; Buxton M; Asare AL; Rugo HS; Schwab RB; Helsten T; Hylton NM; van 't Veer L; Perlmutter J; DeMichele AM; Yee D; Berry DA; Esserman LJ
JAMA Oncol; 2021 Nov; 7(11):1654-1663. PubMed ID: 34529000
[TBL] [Abstract][Full Text] [Related]
39. Assessment of residual cancer burden and survival in neoadjuvant chemotherapy of inoperable stage III breast cancer: A ten-year follow-up analysis in Vietnam.
Pham HK; Le TD; Nguyen TP; Le TU; Ta HH; Nguyen VC
Pathol Res Pract; 2024 Feb; 254():155099. PubMed ID: 38244433
[TBL] [Abstract][Full Text] [Related]
40. Validation of the AJCC 8th prognostic system for breast cancer in an Asian healthcare setting.
Wong RX; Wong FY; Lim J; Lian WX; Yap YS
Breast; 2018 Aug; 40():38-44. PubMed ID: 29677569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]